Metagenomi Therapeutics Current Ratio 2022-2026 | MGX
Metagenomi Therapeutics current ratio from 2022 to 2026. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Metagenomi Therapeutics Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2026-06-30 | $0.12B | $0.03B | 4.50 |
| 2026-03-31 | $0.15B | $0.02B | 6.43 |
| 2025-12-31 | $0.17B | $0.02B | 7.22 |
| 2025-09-30 | $0.19B | $0.03B | 6.42 |
| 2025-06-30 | $0.21B | $0.03B | 6.36 |
| 2025-03-31 | $0.23B | $0.04B | 5.85 |
| 2024-12-31 | $0.26B | $0.04B | 6.91 |
| 2024-09-30 | $0.28B | $0.05B | 6.18 |
| 2024-06-30 | $0.31B | $0.05B | 5.82 |
| 2024-03-31 | $0.34B | $0.07B | 4.75 |
| 2023-12-31 | $0.28B | $0.07B | 4.04 |
| 2023-09-30 | $0.00B | 0.00 | |
| 2023-06-30 | $0.00B | 0.00 | |
| 2023-03-31 | $0.00B | 0.00 | |
| 2022-12-31 | $0.37B | $0.05B | 7.56 |
| 2021-12-31 | $0.11B | $0.03B | 4.33 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.042B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $45.423B | 17.88 |
| BridgeBio Pharma (BBIO) | United States | $13.021B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $10.175B | 25.94 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.445B | 20.49 |
| Bausch Health Cos (BHC) | Canada | $2.121B | 1.32 |
| Personalis (PSNL) | United States | $1.717B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.636B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.005B | 9.45 |
| Assembly Biosciences (ASMB) | United States | $0.508B | 24.48 |
| Sol-Gel Technologies (SLGL) | Israel | $0.169B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |